Pulmatrix wins US patent for new composition of matter covering iSPERSE technology.
M2 EQUITYBITES-September 3, 2015-Pulmatrix wins US patent for new composition of matter covering iSPERSE technology
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company Pulmatrix (NasdaqCM:PULM) reported on Wednesday the receipt of the US patent for the underlying iSPERSE inhaled dry powder technology.
The company's US patent 9,119,778 broadly covers small, dense and dispersible dry powders that are comprised of proprietary combinations of divalent cation salts and excipients. These patented dry powders have the potential to enable and/or improve new approaches for the treatment of lung disease and to facilitate greater efficiency in the delivery of pharmaceuticals to the lungs.
In conjunction, the company now has 37 issued patents worldwide covering the iSPERSE technology through at least 2030.
According to the company, the iSPERSE (inhaled Small Particles Easily Respirable and Emitted) technology has the potential to solve significant limitations of other inhalation technologies available today, such as nebulizers, metered dose inhalers, and conventional lactose blend dry powder inhalers.
These iSPERSE particles are engineered to be small, dense and easily dispersible upon inhalation, thereby delivering the drugs more efficiently to the airways, said the company.
This targeted airway delivery of drugs reduces systemic exposure and potential side effects. Unlike other traditional inhalation technologies, iSPERSE is flow rate independent, providing reliable dose delivery across patient populations regardless of the status of patient lung function, concluded the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Sep 3, 2015|
|Previous Article:||Byggmax to open new store in Eurostop Arlandastad in spring 2016.|
|Next Article:||Silver Spring Networks announces grant of inducement awards to CEO and President.|